Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2025

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: A pooled analysis of patients from the Phase 3 KEEPsAKE 1 and 2 studies

RMD Open 2025;11:e005522 Doi:10.1136/rmdopen-2025-005522

Ogdie A,

Ranza R,

Chen M,

Shi L,

Iyile T,

Lippe R,

Gossec L

Treatment with risankizumab provides durable improvement in the signs and symptoms of PsA across all the GRAPPA disease domains and related conditions. This post hoc analysis by Coates et al. aimed to assess the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA.

Keywords:

Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy

RMD Open 2025;11:e005-21 Doi: 10.1136/rmdopen-2025-005521

Winthrop KL,

Klaff J,

Penn SK,

Liu Y,

García C,

Mysler E,

Wells AF,

Bu X,

Fish I,

Chen M,

Cunningham AL

Most patients vaccinated with RZV while using UPA 15mg QD and background MTX achieved satisfactory humoral and cell-mediated immune responses to recombinant zoster vaccine (RZV) at Weeks 4, 16 and 60. Winthrop et al. evaluated the immunogenicity of RZV through Week 60 in patients with RA who were receiving UPA 15mg QD and background MTX.

Keywords:

January 2025

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat through study

Lancet 2024;404:2423–36 doi: 10.1016/S0140-6736(24)01762-8

Chen M,

Ghosh S,

Hon E,

Lin Z,

Sands BE; for the VIVID Study Group

Ferrante et al. conducted a phase 3 trial evaluating the efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease. The study demonstrated that mirikizumab significantly improved clinical and endoscopic outcomes compared with placebo at week 52, with a favourable safety profile and tolerable adverse events.

Keywords:

May 2024

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

N Engl J Med 2023; 388:1966–1980 doi: 10.1056/NEJMoa2212728

Louis E,

Chen M,

Begun J,

Liu J,

Geng Z,

Feng T,

Dubcenco E,

Colombel J-F

Upadacitinib was associated with higher percentages of remission and endoscopic response regardless of previous failure of biologic therapy. This paper reports the Phase 3 efficacy and safety results of upadacitinib in patients with moderate-to-severe Crohn’s disease.

Keywords:

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three Phase 3, multicentre, double-blind, randomised trials

Lancet 2022;399(10341):2113–28 doi: 10.1016/S0140-6736(22)00581-5

Zhou W,

Chen MH,

Huang B,

Xie W,

Liu J,

Weinreich MA,

Panaccione R

The results of two induction studies (UC1 and UC2) and a maintenance study (UC3) show upadacitinib superiority to placebo in treating ulcerative colitis (UC). Rates of clinical remission were significantly higher for all upadacitinib doses versus placebo in all three studies.

Keywords:

April 2024

Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the Phase 3 KEEPsAKE1 randomized clinical trial

Rheumatol Ther 2024 doi: 10.1007/s40744-024-00654-5 Epub ahead of print

Papp K,

White D,

Lippe R,

Chen M,

Risankizumab therapy was associated with significant and sustained improvement in multiple disease domains from Week 52 through Week 100, compared with placebo. Kristensen et al. investigated the safety, efficacy and tolerability of 100-week risankizumab therapy in PsA patients with previous inadequate response to ≥1 csDMARD, using data from KEEPsAKE 1 trial.